NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alzamend Neuro, Inc. (ALZN) Stock Analysis

Alzamend Neuro, Inc. (ALZN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALZN

$1.25

−$0.05 (−3.85%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALZN with… →

ALZN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.39
Previous Close
$1.30
Day's Range
1.25–1.39
52-Week Range
0.84–2.68
Volume
10.53K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$6.03M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.30
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.77M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.83M
1-Year Return
−47.92%
Dividend and dates
Avg Volume
81.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALZN closed at $1.25, −47.92% over 1 year.

Alzamend Neuro, Inc. (ALZN) has a market capitalization of $6.03M.

In fiscal 2025, ALZN reported revenue of $0.00.

ALZN Stock Return by Calendar Year

Alzamend Neuro, Inc. (ALZN) return since Jun 2021: what $10,000 became

1 year
$10,000 $5,208
−47.92%
5 years
$10,000 $4
−99.96%
Since Jun 2021
$10,000 $0.69
−99.99%

If you had invested $10,000 in Alzamend Neuro, Inc. (ALZN) at the close on June 15, 2021, the earliest close on record here, it would have been worth $0.69 at the close on October 21, 2026: −99.99% in total, −83.34% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−31.32%
2025−82.57%
2024−86.97%
2023−89.50%
2022−70.26%
2021 (partial year)−85.93%

As of October 21, 2026.

ALZN Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.77M—
2024$0.00−$4.51M—
2023$0.00−$9.95M—
2022$0.00−$14.88M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.77M−$8.77M—
2024$0.00—−$4.50M−$4.51M—
2023$0.00—−$9.94M−$9.95M—
2022$0.00—−$14.87M−$14.88M—

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alzamend Neuro, Inc. (ALZN) carries a market capitalisation of $6.03M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 4.

ALZN last closed at $1.25 on October 21, 2026. That is −$0.05 (−3.85%) against the previous close. The 52-week range on file runs from $0.84 to $2.68. The latest close sits 48.81% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.77M. Trailing earnings per share are −2.3.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.27. Daily returns over the trailing 5 years annualize to a volatility of 125.1%. The trailing one-year total return is −47.92%. Across 5 years the annualized return works out at −78.83%.

Growth & Income

The record shows no dividend for ALZN.

2026 is still running; the total return is −31.32% year to date. The strongest complete calendar year on file is 2022 at −70.26%; the weakest is 2023 at −89.50%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Alzamend Neuro, Inc. (ALZN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alzamend Neuro, Inc. ALZN $6.03M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alzamend Neuro, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Visit website →